SCHEMBL23457486

SCHEMBL23457486

N#Cc1ccc(-c2ccc(Oc3c[nH]nn3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.41
MAP3K8 P41279 1/20 0.40
MAP2K1 Q02750 1/20 0.40
MMP3 P08254 2/20 0.39
MAP4K4 O95819 1/20 0.39
MMP2 P08253 3/20 0.39
PGR P06401 1/20 0.38
PARP15 Q460N3 1/20 0.38
PARP10 Q53GL7 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
HRH2 P25021 2/20 0.38
HRH1 P35367 2/20 0.38
HRH3 Q9Y5N1 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CHEK2 O96017 1/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23457541 0.78 HAO1 (0.54) MAP3K8MAP2K1KDM4ESMN1; SMN2MEN1
SCHEMBL2076795 0.74 GABRA1 (0.42) CYP19A1MMP3HRH3RAB9ACYP11B2
SCHEMBL23457568 0.73 HAO1 (0.58) KDM4ECHEK2MEN1MAPTRAB9A
SCHEMBL29699402 0.73 HAO1 (0.58) KDM4ECHEK2MEN1MAPTRAB9A
SCHEMBL23457602 0.72 PARP10 (0.53) MAP3K8MAP2K1MAP4K4PARP15PARP10
SCHEMBL23457563 0.72 ALDH1A1 (0.53) CHEK2
SCHEMBL8308457 0.71 MAP4K4 (0.44) CYP19A1MAP4K4PGRPARP15PARP10
SCHEMBL2520984 0.71 BCAT2 (0.47) KDM4ESMN1; SMN2MEN1MAPTMAPK1
SCHEMBL23457481 0.70 MAOB (0.46) MMP3CYP11B2NOTUM
SCHEMBL7041250 0.70 PARP15 (0.63) CYP19A1MMP3PGRPARP15PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CYP19A1 1433/4885MAP3K8 2976/4885MAP2K1 4016/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CYP19A1 1400/4885MAP3K8 3027/4885MAP2K1 3968/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT CYP19A1 1433/4885MAP3K8 2976/4885MAP2K1 4016/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CYP19A1 1433/4885MAP3K8 2976/4885MAP2K1 4016/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CYP19A1 1433/4885MAP3K8 2976/4885MAP2K1 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.